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Background: Helicobacter pylori gastritis may progress to glandular atrophy and intestinal metaplasia,
conditions that predispose to gastric cancer. Profound suppression of gastric acid is associated with
increased severity of H pylori gastritis. This prospective randomised study aimed to investigate whether H
pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-
oesophageal reflux disease (GORD).
Methods: A total of 231 H pylori positive GORD patients who had been treated for >12 months with
omeprazole maintenance therapy (OM) were randomised to either continuation of OM (OM only;
n = 120) or OM plus a one week course of omeprazole, amoxycillin, and clarithromycin (OM triple;
n = 111). Endoscopy with standardised biopsy sampling as well as symptom evaluation were performed at
baseline and after one and two years. Gastritis was assessed according to the Sydney classification system
for activity, inflammation, atrophy, intestinal metaplasia, and H pylori density.
Results: Corpus gastritis activity at entry was moderate or severe in 50% and 55% of the OM only and OM
triple groups, respectively. In the OM triple group, H pylori was eradicated in 90 (88%) patients, and
activity and inflammation decreased substantially in both the antrum and corpus (p,0.001, baseline v two
years). Atrophic gastritis also improved in the corpus (p,0.001) but not in the antrum. In the 83 OM only
patients with continuing infection, there was no change in antral and corpus gastritis activity or atrophy,
but inflammation increased (p,0.01). H pylori eradication did not alter the dose of omeprazole required,
or reflux symptoms.
Conclusions: Most H pylori positive GORD patients have a corpus predominant pangastritis during
omeprazole maintenance therapy. Eradication of H pylori eliminates gastric mucosal inflammation and
induces regression of corpus glandular atrophy. H pylori eradication did not worsen reflux disease or lead
to a need for increased omeprazole maintenance dose. We therefore recommend eradication of H pylori
in GORD patients receiving long term acid suppression.
H
elicobacter pylori causes chronic gastritis in almost all
subjects colonised with this bacterium. This can
ultimately lead to loss of gastric glands.1 The resulting
atrophic gastritis and intestinal metaplasia increase the risk
of dysplasia and gastric cancer.2 Most cases of gastric cancer
occur on a background of H pylori infection and chronic
gastritis with gland loss.3–5 The rate of progression to atrophic
gastritis is slow and dependent on the severity and distribu-
tion of gastritis.
In subjects with intact acid production, gastritis is largely
confined to the gastric antrum, and the rate of progression to
atrophy in the corpus is low.1 In contrast, the increase in
corpus gastritis activity associated with long term acid
suppressant therapy6–8 can be expected to accelerate the
development of atrophic gastritis in the corpus mucosa over a
time frame of years. This possibility has been addressed
in two longitudinal studies in which cohorts of H pylori
infected patients receiving or not receiving long term acid
suppression were compared. Accelerated development of
atrophy was concluded by Kuipers and colleagues9 but was
not confirmed by Lundell and colleagues.10 Other cohort
studies reported development of atrophic gastritis within
several years of treatment with profound acid suppressive
therapy for gastro-oesophageal reflux disease (GORD) but
these studies were uncontrolled.11–14
The possibility that acid suppressive therapy accelerates the
development of atrophy is clinically relevant because many
GORD patients who are infected with H pylori require
maintenance proton pump inhibitor (PPI) therapy. The
European Helicobacter pylori Study Group, among others, has
therefore advised that H pylori should be eradicated in GORD
patients treated with PPI maintenance therapy.15 However, to
date there are only limited data on whether this intervention
substantially alters the pattern and severity of H pylori
associated gastritis during continued PPI therapy.16 17 There
have also been concerns that the adequacy of control of reflux
disease by therapy could be impaired by H pylori eradication.
We therefore performed a prospective controlled trial which
evaluated the effects of H pylori eradication on changes
in gastric histology and symptom control over two years,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: GORD, gastro-oesophageal reflux disease; PPI, proton
pump inhibitor; OM, omeprazole; OAC, omeprazole, amoxycillin,
clarithromycin; OMC, omeprazole, metronidazole, clarithromycin
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in H pylori infected GORD patients already established on
omeprazole maintenance therapy.
METHODS
Study overview
Eligible H pylori infected patients were randomised to
continued omeprazole treatment without H pylori eradication
(OM only) or continued omeprazole after a one week
omeprazole based triple H pylori eradication therapy (OM
triple). Patients underwent endoscopy, biopsy, and clinical
assessments at baseline, one year, and at study completion
after two years. Patients and clinicians involved in the study
remained blinded as to the H pylori negativity of each
individual throughout the study.
Patients
Patients were required to be at least 18 years old, have a
history of GORD, and have been treated for at least
12 months with daily omeprazole maintenance therapy.
GORD had to have been diagnosed by endoscopy, or by
24 hour oesophageal pH metry. Patients were excluded from
the study if they had a history of complicated peptic ulcer
disease or if they were known to have Zollinger-Ellison
syndrome or another concomitant disorder which could
interfere with the study assessment, such as severe cardiac,
hepatic, or renal disease, or a suspected or confirmed
malignancy. Patients who required continuous treatment
with drugs that could interact with clarithromycin were also
excluded. The protocol was approved by the ethics commit-
tees of the 42 participating centres in seven countries (see
appendix). The majority of these centres were general
hospitals. Informed written consent was obtained from each
patient.
Protocol
All eligible patients underwent upper gastrointestinal endo-
scopy. Endoscopic findings were recorded systematically.
Reflux oesophagitis was classified according to the Savary
Miller system.18 Barrett’s oesophagus was defined as the
presence of cylindrical epithelium with intestinal metaplasia
in the distal oesophagus over a distance of 3 cm or more, and
hiatus hernia as extension of the gastric folds to at least 2 cm
above the diaphragm impression. Biopsies for histology and
H pylori culture were taken with standard biopsy forceps from
the antrum, 2 cm proximal to the pylorus (62), and from the
corpus along the greater curvature 10 cm below the cardia
(65). In the case of a Barrett’s oesophagus or specific lesions,
additional samples were obtained but these were not part of
this study. Patients were considered to be H pylori positive if
either culture or histology, or both, showed infection in one
or more samples. These patients were eligible for inclusion,
and were randomised to either omeprazole alone (OM only
group) or OM plus H pylori eradication therapy given in the
first week (OM triple group) (fig 1). Randomisation occurred
at a ratio of 1:1 for each treatment arm, within blocks of four
consecutive patients per participating centre. The allocation
sequence was computer generated and distributed by the
central study coordinator. Participants were enrolled and
assigned to their study treatment by the local investigator.
Eradication therapy consisted of a seven day course of
omeprazole 20 mg twice daily, amoxycillin 1000 mg twice
daily, and clarithromycin 500 mg twice daily (OAC). Patients
allergic to amoxycillin received omeprazole in combination
with metronidazole 400 mg twice daily and clarithromycin
250 mg twice daily (OMC). After the first week, patients
continued omeprazole at the dose they were using prior to
inclusion in the study.
During follow up, adjustment of the dose of omeprazole
was permitted on the basis of symptom status or endoscopic
findings. Decisions on dose adjustment were left to the
patient and treating physician. Comedication at any time was
noted. At the one and two year follow up visits, endoscopy
and biopsy were repeated. Patients scored their reflux
symptom status for the seven days prior to inclusion and
the follow up visits on a scale of 0–3, representing: (0) no
symptoms; (1) occasional episodes of reflux complaints but
easily tolerated and not interfering with normal activities; (2)
daily episodes and occasionally interfering with normal
activities; and (3) daily episodes and constantly interfering
with normal activities.
Histological and culture methods
Histological methods were as described previously.9 In brief,
5 mm thick sections stained with haematoxylin-eosin were
used for standard histological evaluation. H pylori was
detected by a modified silver impregnation method.19
Sevier-Munger silver staining,20 and sometimes Grimelius
staining also,21 were used to detect argyrophil neuroendocrine
cells (mainly enterochromaffin-like cells). Slides were
encoded, scrambled, and stained together so that the
pathologist was blinded to the timings of biopsies and the
identity of the patient. The pathologist (NH) was isolated
from all participating centres and reviewed the encoded
slides without any access to clinical or endoscopic data,
timing of sampling, or previous results from the same
patient. He graded the encoded samples according to the
Sydney classification system.22 The following items were
evaluated separately: H pylori density, any acute inflamma-
tory component of gastritis (especially the amount of
neutrophil infiltration), chronic inflammatory gastritis (espe-
cially the amount of lymphoplasmacytic infiltration), gastric
glandular atrophy on the basis of gland loss, and intestinal
metaplasia. All of these items were scored from 0 (absent), to
1 (mild), 2 (moderate), or 3 (severe), as defined in the
_
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Sydney classification system. The classification of Solcia et al
was used to score the argyrophil cell pattern23; this ranges
from normal (0) to diffuse (1), linear (2), or micronodular
hyperplasia (3), and further includes adenomatoid hyperpla-
sia, dysplasia, intramucosal neoplasm, and invasive neo-
plasm. Culture of H pylori was performed under
microaerophilic conditions using blood agar plates.
Statistical analysis
Statistical analysis was performed using Wilcoxon’s rank
sum test for changes from baseline to the last visit in terms of
the number of severity grades.24 Two tailed p values smaller
than 0.01 were considered to indicate statistical significance.
The main analysis was comparison of treatment arms,
irrespective of the H pylori status of individual patients
during follow up. A secondary analysis compared outcomes
in those patients in the OM triple group in whom H pylori
eradication had succeeded with those in the OM only group
shown to remain H pylori positive at the two year last visit. A
sample size of 225 evaluable patients equally distributed over
both groups was calculated to allow demonstration of a 10%
difference in the proportion of patients with atrophic gastritis
in both groups with an 85% test power.
RESULTS
Patients
In total, 624 potentially eligible GORD patients who met all of
the criteria for randomisation and who had been treated for
at least 12 months with omeprazole underwent screening
endoscopy with biopsy sampling (fig 2). A total of 234
(37.5%) of these patients were H pylori positive. Because of
error, three eligible patients were never randomised and were
therefore excluded from further analysis. Of the remaining
231 patients (126 men and 105 women), 120 were
randomised to OM only and 111 to OM triple. Of the latter,
100 received OAC and 11 OMC. The two randomised groups
did not differ with respect to baseline characteristics (table 1).
Histology
Analysis according to treatment arm
Corpus
Baseline or follow up corpus biopsy specimens were unavail-
able for 11 patients in the OM only group and for nine
patients in the OM triple group; hence complete data were
available for 211 (109 v 102) patients.
Corpus gastritis activity was moderate to severe in 50% of
patients in the OM only group at the start of the study and in
50% and 48% at one and two years, respectively (table 2). The
OM triple group was strikingly different at two years, as
moderate to severe gastritis was present in 55% at baseline
and in only 4% and 5% at one and two years, respectively.
This difference in the change in gastritis activity between the
groups over the two years was highly significant (p,0.001).
Moderate to severe chronic inflammation was present in
69% of OM only patients at baseline and in 80% and 75% at
one and two years (table 2). By comparison, moderate to
severe chronic inflammation was observed in the OM triple
group in 73% at baseline and in only 11% and 13% at one and
two years (comparison between groups, p,0.001).
Corpus glandular atrophy of any degree was present in 24%
of the OM only group at baseline and in 23% at one and two
years (fig 3). If only moderate to severe atrophy were
considered, this was present in the OM only group in 11% at
baseline and in 13% and 12% at one and two years,
respectively. In the OM triple group, corpus mucosa atrophy
of any degree was present in 27% of patients at baseline. In
contrast with the lack of effect seen in the OM only group,
the prevalence of atrophy of any severity decreased to 19%
and 14%, respectively, one and two years after H pylori
eradication therapy. The proportion of OM triple treated
patients who had moderate to severe atrophy changed from
15% at baseline to 3% and 5% at one and two years,
respectively (comparison between groups, p,0.001) (table 2).
Corpus intestinal metaplasia was uncommon at baseline,
and did not change in either group at two years (table 2). All
cases of intestinal metaplasia were type I.
Corpus argyrophil cell hyperplasia did not change sig-
nificantly over time in the OM only group, increasing from
20% at baseline to 29% at two years. In the OM triple group,
the proportion of patients with argyrophil cell hyperplasia
decreased significantly from 29% at baseline to 19% at two
years (p,0.001). Argyrophil cell hyperplasia was significantly
more common in patients with glandular atrophy; at two
years hyperplasia was present in 31/41 (76%) patients with
glandular atrophy versus 21/173 (12%) patients without
atrophy ( p,0.001).
Corpus dysplasia was found in one patient in the OM only
group in the corpus biopsy at 12 months. Subsequent
endoscopy with more extensive biopsy sampling confirmed
Omeprazole/
triple therapy
111
Omeprazole
120
Not randomised
3
Randomised
231
H pylori positive
234
H pylori negative
390
Screened
624
Figure 2 Patient flow chart.
Table 1 Baseline characteristics of the two groups
(omeprazole alone (OM only) or OM plus H pylori
eradication therapy given in the first week (OM triple))
OM only
(n = 120)
OM triple
(n = 111)
Sex (M/F) 72/48 54/57
Age (y)
Mean 62.4 61.8
SD 12.0 12.3
Min 31 27
Max 82 86
No of treatment years with
omeprazole at baseline
Mean 5.3 5.3
SD 3.1 3.0
Min 1.0 0.9
Max 12.9 11.4
Omeprazole maintenance dose (mg)
Mean 26.1 26.7
SD 12.0 13.2
Min 10.0 10.0
Max 80.0 80.0
Duration of GORD (y)
1–5 30 26
6–10 25 26
.10 65 59
Hiatus hernia
Present 52 44
Barrett’s oesophagus
Present 24 27
GORD, gastro-oesophageal reflux disease.
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this and gastric resection revealed a 363 cm T2 adenocarci-
noma. No signs of recurrent or metastatic disease have been
found in this patient at follow up.
Corpus H pylori density at baseline was moderate or severe
in about two thirds of patients in both treatment groups
(table 2).
Antrum
Follow up antrum biopsy specimens were unavailable from
13 OM only and 15 OM triple patients. Accordingly, the data
summarised in table 3 are for 203 (107 versus 96) patients.
Antral gastritis activity was predominantly mild or absent
in both groups at baseline and did not change significantly
over the two years of observation in the OM only group. The
OM triple group showed a highly significant (p,0.001)
virtual disappearance of antral activity at two years compared
with the OM only group.
Antral chronic gastritis at baseline was highly prevalent for
both groups, and remained so for the OM only group,
although this was mild in slightly more than half of the
patients. The OM triple group showed a substantial improve-
ment in antral inflammation at two years (p,0.01).
Antral glandular atrophy did not change in either group
over time and was moderate to severe in only 5% of patients
at two years.
Antral intestinal metaplasia was also not influenced by
H pylori eradication but was present in 19% of patients at two
years, with no differences between the groups.
Antral H pylori density was either mild or could not be
assessed because of absence of visible bacteria in the great
majority of patients at baseline.
Analysis according to H pylori status
At two years, 90 (88%) OM triple patients and 29 (24%) OM
only patients had become H pylori negative. Of the latter
group, 10 were documented to have used antibiotics during
follow up. Tables 4 and 5 show the data according to H pylori
status at two years for the subgroups of proven H pylori
negative OM triple patients and persistently H pylori positive
OM only patients. From a comparison with tables 2 and 3, it
can be seen that changes in gastric histology over time in the
OM only and OM triple groups were related to H pylori status.
In other words, patients in whom OM triple failed to
eradicate H pylori showed a similar persistence of chronic
active gastritis during follow up as those treated with OM
only. This contrasted clearly with patients in the OM only
group who became H pylori negative in whom there was a
similar improvement in histology as in those OM triple
treated patients in whom H pylori eradication was successful.
Symptoms, omeprazole dose, and endoscopic
oesophagitis
There were no significant changes in the severity of GORD
symptoms in either treatment group during follow up, with
median symptom scores of 0 and less than 10% prevalence of
moderate to severe symptoms in both groups at all three
visits (fig 4). The prevalence of any degree of reflux
symptoms at the two year visit was 25% in the OM only
group and 34% in the OM triple group (p = 0.15). There was
no change in endoscopic signs of oesophagitis over time in
Table 2 Histological characteristics of the corpus at baseline and at the last visit, for
patients randomly assigned to omeprazole alone (OM only) or to eradication triple
therapy (OM triple)
Variable Score
OM only (by treatment
group)
OM triple (by treatment
group)
p ValueBaseline Last visit Baseline Last visit
Activity None 16 25 12 92 ,0.001
Mild 39 32 34 5
Moderate 37 29 37 4
Severe 17 23 19 1
Inflammation None 5 12 9 43 ,0.001
Mild 29 15 19 46
Moderate 52 45 51 11
Severe 23 37 23 2
Atrophy None 82 84 74 88 ,0.001
Mild 15 12 13 9
Moderate 7 7 11 5
Severe 5 6 4
Intestinal metaplasia None 103 106 97 95 0.227
Mild 6 3 4 7
Moderate 1
Severe
H pylori None 9 29 7 92 ,0.001
Mild 34 18 32 1
Moderate 21 18 15 4
Severe 45 44 48 5
p values are for the differences in changes in status from baseline to two years between the two groups.
Data are shown as number of patients with each score.
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Figure 3 Prevalence of corpus atrophic gastritis in patients randomly
assigned to omeprazole alone (OM only) or to eradication triple therapy
(OM triple). The bars represent per cent corpus atrophic gastritis at
baseline, and after one and two years of follow up for the OM only and
OM triple group.
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either group during follow up. For both groups, erosive or
ulcerative oesophagitis was present in less than 8% at the one
and two year follow ups (fig 5).
The protocol allowed investigators to adjust the omeprazole
dose according to the adequacy of the control of GORD.
However, in both groups, the omeprazole dose required did
not change over time. The mean daily dose in the OM only
group was 26.1 (range 10–80) mg at baseline and 28.1 (range
10–120) mg at two years. In the OM triple group, the mean
daily omeprazole dose was 26.7 mg at baseline (range 10–80)
and 29.0 (range 20–80) mg at two years (p.0.20) (fig 6).
DISCUSSION
Our study has provided important insights into the issues
that relate to H pylori infection, reflux disease, and its
treatment. In contrast with previous studies, ours was
randomised, prospective, double blind, well powered, and
specifically designed to investigate issues concerning H pylori
infection and long term acid suppression in reflux disease. As
such, it addressed the criticisms and concerns that were
raised in previous studies such as in our initial cohort study.9
Interpretation of the gastric biopsies was made as uniform
and objective as possible by the use of predefined criteria, and
Table 3 Histological characteristics of the antrum at baseline and at the last visit, for
patients randomly assigned to omeprazole alone (OM only) or to eradication triple
therapy (OM triple)
Variable Score
OM only (by treatment
group)
OM triple (by treatment
group)
p ValueBaseline Last visit Baseline Last visit
Activity None 48 64 39 85 ,0.001
Mild 45 32 43 11
Moderate 8 7 9
Severe 6 4 5
Inflammation None 9 14 8 30 ,0.001
Mild 63 49 53 59
Moderate 30 37 30 7
Severe 5 7 5
Atrophy None 85 91 73 80 0.953
Mild 17 12 16 9
Moderate 3 2 4 2
Severe 2 2 2 4
Intestinal metaplasia None 87 88 82 77 0.278
Mild 13 15 7 13
Moderate 5 2 5 3
Severe 2 2 2 3
H pylori None 41 67 37 89 ,0.001
Mild 46 18 38 5
Moderate 7 6 7
Severe 13 16 14 2
p values are for the differences in changes in status from baseline to two years between the two groups.
Data are number of patients with each score.
Table 4 Histological characteristics of the corpus at baseline and at the last visit for those
patients randomly assigned to omeprazole alone (OM only) who remained H pylori
positive versus those assigned to eradication triple therapy (OM triple) who became H
pylori negative
Variable Score
OM only (H pylori +ve
patients at 2 y)
OM triple (H pylori 2ve
patients at 2 y)
p ValueBaseline Last visit Baseline Last visit
Activity None 1 3 9 89 ,0.001
Mild 33 27 30 1
Moderate 32 29 33
Severe 16 23 18
Inflammation None 8 43 ,0.001
Mild 17 6 16 44
Moderate 43 39 45 3
Severe 22 37 21
Atrophy None 58 60 66 80 0.001
Mild 14 11 11 7
Moderate 6 6 11 3
Severe 4 5 2
Intestinal metaplasia None 79 80 85 83 0.688
Mild 3 2 4 7
Moderate 1
Severe
H pylori None 3 2 6 90 ,0.001
Mild 19 18 29
Moderate 20 18 14
Severe 40 44 41
p values are for the differences in changes in status from baseline to two years between the two groups.
Data are number of patients with each score.
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by blinded assessment of all biopsies by having one
histopathologist very experienced in the field. The major
findings of the present study were: (1) moderate to severe
corpus gastritis is highly prevalent among H pylori positive
reflux disease patients who are receiving daily long term PPI
therapy; (2) H pylori eradication results in healing of most of
the gastritis, despite continued PPI therapy; and (3) there is
no clinically significant adverse impact on the severity of
reflux disease or its control by omeprazole in the two years
following H pylori eradication, during which time gastritis
largely healed.
Colonisation of the gastric mucosa with H pylori almost
invariably causes chronic active gastritis.1 25 There is general
agreement that acid suppressant therapy changes the usually
antral predominant gastritis to one that is corpus predomi-
nant.6 7 The baseline data show that severe corpus gastritis is
very prevalent in reflux disease patients who are H pylori
positive and receive PPI therapy. This finding should be a
guide for a clinical management strategy. Overall, corpus
gastritis activity was moderate in 35% and severe in 17%, and
chronic corpus inflammation was moderate in 25% and
severe in 22%. Corpus atrophy of any degree was present in
26%, being moderate in 8.5% and severe in 4.3%. These data
show a substantial impact of H pylori infection on the corpus
mucosa in a high proportion of patients. This impact would
be expected to become more severe over time, which is
relevant as the average age of our patients was 62 years.
The pattern of gastritis seen during acid suppressant
therapy is relevant as this pattern is associated with an
increased risk for the development of gastric cancer, primarily
as a result of progression to gastric atrophy,9 26 but also by
itself without the presence of atrophy, as was shown in a
recent longitudinal study.5 The present study was not
designed to address the question of whether PPI therapy
related changes in gastritis increase the rate of development
of gastric atrophy or intestinal metaplasia. Review of the
Table 5 Histological characteristics of the antrum at baseline and at the last visit for those
patients randomly assigned to omeprazole alone (OM only) who remained H pylori
positive versus those assigned to eradication triple therapy (OM triple) who became H
pylori negative
Variable Score
OM only (H pylori +ve
patients at 2 y)
OM triple (H pylori -ve
patients at 2 y)
p ValueBaseline Last visit Baseline Last visit
Activity None 29 40 32 78 ,0.001
Mild 38 29 38 6
Moderate 6 7 9
Severe 6 3 5
Inflammation None 4 3 8 30 ,0.001
Mild 45 34 46 51
Moderate 25 35 25 3
Severe 5 7 5
Atrophy None 85 91 73 80 0.682
Mild 17 12 16 9
Moderate 3 2 4 2
Severe 2 2 2 4
Intestinal metaplasia None 61 64 72 68 0.113
Mild 13 12 7 11
Moderate 3 2 3 3
Severe 2 1 2 2
Helicobacter pylori None 31 39 33 84 ,0.001
Mild 29 18 33
Moderate 7 6 6
Severe 12 16 12
p values are for the differences in changes in status from baseline to two years between the two groups.
Data are number of patients with each score.
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Figure 4 Overall reflux symptoms in patients randomly assigned to
omeprazole alone (OM only) or to eradication triple therapy (OM triple).
The bars represent the severity of reflux symptoms at baseline, and after
one year and two years of follow up for the OM only and OM triple
groups. The results are represented as actual numbers of patients
(presented to the right of each bar segment).
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Figure 5 Grade of oesophagitis in patients randomly assigned to
omeprazole alone (OM only) or to eradication triple therapy (OM triple).
The bars represent the severity of grade of oesophagitis at baseline, and
after one year and two years of follow up for the OM only and OM triple
group. The results are represented as actual numbers of patients.
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available data in 1996 led the US Food and Drug
Administration to conclude that there were insufficient data
to justify eradication of H pylori in patients taking long term
acid suppressant therapy, especially as there were then
substantial theoretical concerns that eradication of H pylori
would make reflux disease more difficult to control. This
concern has been largely allayed by recent data. Three recent
randomised studies showed that H pylori eradication did not
affect the relapse rate of reflux disease either during ongoing
PPI therapy16 or after withdrawal of such therapy.27 28
Previous studies show that H pylori eradication leads to
healing of gastritis within 12–24 months. Two randomised
smaller studies have shown that when H pylori is eradicated
at the start of omeprazole maintenance therapy there is
resolution of gastritis and prevention of the onset of a corpus
predominant pangastritis.16 17 The present study confirms
these findings. Chronic active pangastritis persisted in
patients who remained H pylori positive but disappeared in
most patients who received H pylori eradication treatment.
Our study provides important insights into the effect of H
pylori eradication on glandular atrophy in patients receiving
long term PPI therapy. Previously available data on the effect
of H pylori eradication on atrophic gastritis are limited and
conflicting, most coming from uncontrolled cohort studies,
usually with a limited sample size, short follow up periods,
and unblinded suboptimal protocols for histological evalua-
tion.29–38 Some of these studies have suggested that H pylori
eradication could lead to improvement in glandular atrophy
and intestinal metaplasia, but others have not. Until now,
there has been only one published randomised controlled
study on this issue.39 The investigators followed 515 H pylori
positive Chinese subjects without specific conditions or
therapy for one year after randomisation to either eradication
treatment or placebo. In subjects who remained H pylori
positive, there was an increase in corpus glandular atrophy
over one year. In subjects who became H pylori negative, acute
and chronic inflammation improved but the changes in
glandular atrophy and intestinal metaplasia could not be
evaluated adequately because of the small number of subjects
with such lesions at baseline. We therefore followed our
patients for two years and analysed the data according to
treatment arm.
The overall prevalence of H pylori associated corpus
glandular atrophy in our study population was 26% at
baseline. This is consistent with other data obtained in
patients who had been using long term PPI therapy.9 10 12 In
the OM only group, the prevalence of glandular atrophy did
not change during the two years of observation (tables 4, 5).
Progression of glandular atrophy has been observed in other
studies in H pylori infected patients with longer follow up
during PPI maintenance therapy.9–12 The lack of evidence of
progression of atrophy in the OM only group in our study can
be explained by the relatively short two year follow up period
of our study. Certainly, conditions that favour atrophy
progression—persistent chronic active corpus gastritis—were
present. The 95% confidence interval for the annual change
in prevalence of atrophic gastritis over time ranged from29%
to +5%. This wide interval fully includes the possibility for
progression of atrophy, as previously observed, which means
that our current data do not contrast with previous
findings.9 10 12 A longer follow up would have enabled
calculation of a narrowed confidence limit but this was not
the purpose of the study. It might be that further progression
of atrophy would occur similar to that observed previously in
other studies9 10 12; it may also be that further development of
atrophic gastritis would not occur as the changes have
already been induced in susceptible individuals. The present
study started with patients who at baseline had already used
omeprazole for a mean of 5.3 years, whereas previous studies
always followed patients from the start of PPI use and never
had a longer mean follow up than approximately six years.12
In contrast with the observations in the OM only group, in
the OM triple group the prevalence of glandular atrophy
decreased. We can thus authoritatively confirm the observa-
tion of several smaller and uncontrolled case studies that H
pylori eradication can lead to restitution of gastric glands and
regression of atrophy. This regression was not restricted to
subjects with mild corpus atrophy but also occurred in
patients with moderate and severe glandular atrophy
(tables 2, 3).
It has been suggested that gland loss is often incorrectly
diagnosed in patients with chronic active gastritis, as the
inflammation may lead to a widening of the intraglandular
space.40 However, in most studies, including our own, the
presence of glandular atrophy was determined by experi-
enced and leading gastrointestinal pathologists9 10 12 17 41 who
used internationally accepted criteria.22 Furthermore, follow
up of H pylori positive GORD patients from the start of PPI
therapy showed a markedly different time pattern for the
evolution of corpus predominant pangastritis versus gland-
ular atrophy, with the first occurring immediately and the
second occurring within the following years.9 10 12 In the
present study, regression of atrophy was also a more gradual
process than resolution of active gastritis. These observations
strongly and consistently support the hypothesis that
inflammation and gland loss are different phenomena. This
is further supported by quantitative histological studies on
the effect of PPI treatment and H pylori eradication in H pylori
positive GORD patients,42 as well as by functional studies
showing an association of atrophy, but not of corpus
predominant pangastritis, with hypergastrinaemia,43 and a
decrease in serum pepsinogen I and vitamin B12.44
Restitution of glands after eradication is a remarkable
phenomenon, which until now has been considered an
unrealistic expectation.45 It is impossible by definition to
blind the pathologist to the H pylori status of the slides under
evaluation. There is therefore the potential for the results to
be biased but this is unlikely to fully explain the marked
results of H pylori eradication on corpus gastritis and atrophy.
Our primary analysis followed the rigorous intention to
treat approach of including data from all available study
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patients. The reported outcomes were influenced by the
inevitable minority of patients in the OM triple group in
whom triple therapy failed to eradicate H pylori and by those
in the OM only group who became H pylori negative.
Normally, if H pylori eradication fails initially, the clinician
would strive to eradicate the infection by retreatment. Our
secondary analysis by H pylori status gives a clearer picture of
what can be achieved with H pylori eradication, and
emphasises how effectively gastritis is reversed despite
continued omeprazole. H pylori eradication in the OM only
group in particular appeared to occur as a result of additional
antibiotic treatment outside of the protocol, mainly for
respiratory infection.
This study adds significantly to the growing evidence that
overall, H pylori eradication has a minimal impact on the
clinical course of reflux disease and its therapy,16 27 28 46 47 or
may even lead to an improvement in symptoms.48 An
exception to this generalisation is the experience from
Japan and Hong Kong.49–51 In East-Asian countries, gastritis
is frequently so severe that it suppresses acid secretion to a
level that renders gastric juice relatively non-injurious to the
oesophageal mucosa. It has been shown that in such patients,
acid secretion recovers substantially following H pylori
eradication52 and that this can lead to the development of
reflux symptoms and generally mild oesophagitis in patients
with previously subclinical symptoms from impairment of
gastro-oesophageal competence.49–51 The structured two year
follow up of patients in the present study showed no evidence
of a clinically significant impact of H pylori eradication on the
efficacy of control of reflux disease by omeprazole, as
assessed by symptoms, endoscopy, and dose of omeprazole
required to control GORD. These data emphasise that the
balance weighs heavily in favour of benefit from H pylori
eradication in H pylori infected GORD patients. This is
consistent with 24 hour oesophageal pH monitoring studies
performed with or without acid suppressant therapy in which
no differences were observed between H pylori positive and
negative reflux disease patients with respect to oesophageal
acid exposure with or without suppressive therapy.53 54
In conclusion, our study has documented that in H pylori
colonised GORD patients on long term proton pump inhibitor
therapy, eradication of H pylori almost completely eliminates
gastritis and may lead to regression of corpus glandular
atrophy. This has no clinically significant adverse impact on
the severity of reflux disease or its control by omeprazole. For
these reasons, we believe that GORD patients who require
long term PPI treatment should be tested for H pylori
infection and treated if positive.
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GI SNAPSHOT
Answer
From question on page 4
A detailed interview disclosed her habit of finger evacuation of the rectum. A diagnosis of self
inflicted rectal ulcer was suspected. Avoidance of rectal digitation was advised. Follow up
colonoscopy showed that the ulcer had healed, indicating that self inflicted injury was the
aetiology.
Rectal ulcer is an infrequent pathology associated with various disorders, including
inflammatory bowel disease, infectious proctitis, mucosal prolapse syndrome (MPS),
ischaemic colitis, and neoplasms. Symptoms of MPS may include a sense of incomplete
rectal evacuation necessitating digital manipulation. Therefore, in addition to the pathological
examination, detailed history is very important to differentiate self inflicted rectal ulcer,
especially from MPS. Enquiry about finger evacuation may be better asked without the
presence of patients’ family members or other medical staff. In conclusion, with an emphasis
of the importance of detailed history, self inflicted rectal ulcer should be recognised as an
important differential diagnosis for the management of anorectal diseases.
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